Effect of Cobalamin Treatment on Clinical Outcomes of Patients with Mild to Moderate Carpal Tunnel Syndrome: A Randomized Double Blinded Controlled Trial

Effect of Cobalamin treatment on clinical outcomes of patients with mild to moderate carpal tunnel syndrome: A randomized double blinded controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220503001

Enrollment

108

Registered

2022-05-03

Start date

2023-01-17

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate carpal tunnel syndrome Carpal tunnel syndrome, Methylcobalamin, Vitamin B12

Interventions

Methycobalamin 1000 mcg/d,Vitamin B1-1-12 1 tab po bid pc (consist of Methycobalamin 1000 mcg/d),Placebo

Experimental Drug,Active Comparator Drug,Placebo Comparator Drug

Methylcobalamin,Vitamin B1-6-12,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 year 2. Diagnosis confirmed by electrodiagnostic study 3. Mild to moderate carpal tunnel syndrome

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Communication disorders 3. End-stage renal or hepatic disease (GFR < 15, Cirrhosis Child C) 4. Steroid use last 10 weeks 5. Other neurologic disorders eg. Cerebrovascular disease, cervical radiculopathy, diabetic neuropathy, peripheral neuropathy

Design outcomes

Primary

Measure	Time frame
Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score at 12 weeks after start drug Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score	—

Secondary

Measure	Time frame
Douleur Neuropathique 4 (DN4) score at 12 weeks after start drug Douleur Neuropathique 4 (DN4) score	—

Countries

Thailand

Contacts

Public ContactThammasak Hunsuwan

Siriraj hospital

thammasak.hun@gmail.com0982656489

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026